Eluracat 20mg/ml Oral Solution for Cats 15ml

Eluracat capromorelin oral solution for cats with poor appetite

Capromorelin is a selective ghrelin receptor agonist. It binds to ghrelin receptors in the hypothalamus to stimulate appetite and in the pituitary to stimulate secretion of growth hormone. The clinical effects of capromorelin in cats are a combination of increased food intake and metabolic changes resulting in weight gain.

Eluracat does not treat the underlying chronic medical condition: it is intended to provide supportive therapy alongside your vet's treatment of that condition.

Key features of Eluracat 20mg/ml Oral Solution for Cats:

• Active ingredient: capromorelin tartrate 20mg per ml (equivalent to 15.4mg capromorelin).
• Once-daily dose by mouth: dosed by bodyweight and given directly into the cat's mouth.
• Oral ml scale syringe included with the 15ml bottle.
• Child-resistant closure: the bottle has a tamper-proof child-resistant cap.
• Use within 3 months of first opening.

For use under veterinary direction

Eluracat is a prescription-only veterinary medicine. Your vet will decide whether it is suitable, particularly for cats with diabetes, heart conditions or liver problems, and how long to give it. See our cat care range and our guide to pet prescriptions.

Always follow the directions and dosage given to you by your prescriber.

Dosage

For oral use.

The recommended dose is 2 mg/kg body weight which is equivalent to 0.1 ml/kg body weight. Eluracat is to be administered once daily directly into the mouth.

The safety in cats less than 10 months old or with less than 2 kg body weight has not been evaluated.

The efficacy has not been established for more than 90 days. The product should only be used for a period of greater than 90 days following a benefit-risk assessment by the responsible veterinary surgeon.

How to give it

1. Remove the cap, insert the dosing syringe, invert the bottle, withdraw the appropriate amount of solution using a ml scale syringe.
2. Return the bottle to the upright position, remove the syringe, replace the cap tightly.
3. Administer the solution into the cat's mouth.
4. Rinse the syringe and the plunger with water and leave apart to dry.

Before use

Do not use:

• in cases of hypersensitivity to the active substance or to any of the excipients.
• in patients with severe haemodynamic instability such as hypovolaemic shock.
• in patients with hypersomatotropism (acromegaly).
• during pregnancy and lactation, or in breeding animals.

Special warnings: Eluracat does not treat the underlying chronic medical conditions but is intended to provide supportive therapy. The efficacy in cats less than 6 years old or with less than 2 kg body weight has not been evaluated. The efficacy has not been established for more than 90 days.

Special precautions for use in animals:

• Eluracat has been shown to increase serum glucose levels in cats, with highly variable effects on individual cats. In non-diabetic cats homeostatic mechanisms adapt to maintain blood glucose levels within normal ranges after a few days. Use in cats with diabetes mellitus has not been evaluated; in cases of diabetes mellitus, use only according to the benefit-risk assessment by the responsible veterinary surgeon.
• Eluracat causes transient reductions in blood pressure and heart rate. In a study in eight healthy male cats, reductions of up to 30% below baseline were observed for approximately four hours following the recommended dose of 2 mg/kg; these were partially mitigated by human interaction followed by feeding. Use only according to a benefit-risk assessment by the vet in patients with congestive heart failure, cardiac arrhythmias, dehydration, anaemia or other conditions that may impair tissue perfusion or oxygenation.
• Use with caution in cats with hepatic dysfunction, as capromorelin is metabolised in the liver.
• The safety in cats less than 10 months old or with less than 2 kg body weight has not been evaluated. The safety for more than 90 days in cats with chronic medical conditions has not been evaluated.

Precautions for the person giving the product:

• Ingestion by children may cause mild and reversible signs of abdominal pain, lethargy, lightheadedness, palpitation, low back pain, feeling warm and increased perspiration. Children should not have access to filled syringes. Do not leave a filled syringe unattended. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
• This product contains parabens and povidone, which may cause allergic reactions. People with known hypersensitivity to these substances should administer it with caution.
• This product may cause eye and skin irritation. Avoid contact with the eyes, skin and mucous membranes. Wash hands after use. In case of accidental eye or skin contact, rinse the affected area immediately with plenty of fresh water. If irritation persists, seek medical advice and show the package leaflet or the label to the physician.

Pregnancy, lactation and fertility: The safety has not been established during reproduction, pregnancy and lactation. Laboratory studies in rats have shown evidence of teratogenic effects. Do not use during pregnancy and lactation. Do not use in breeding animals.

Interactions: Eluracat causes transient decreases in blood pressure and heart rate for up to several hours after dosing, so concurrent use of other drugs that reduce blood pressure and/or heart rate (e.g. sedatives, anaesthetic agents, prazosin, ACE inhibitors) should only be according to a benefit-risk evaluation by the vet. It causes transient elevations in serum glucose levels and insulin resistance, so concurrent use of other drugs that cause such effects (e.g. steroids) should only be according to a benefit-risk evaluation by the vet.

Adverse events and overdose

Very common (more than 1 animal in 10 treated): hypersalivation, at the time of dosing and resolved within a few minutes.

Common (1 to 10 animals in 100 treated): diarrhoea, vomiting, anaemia, skin lesions (on the mouth and chin), dehydration, lethargy, inappetence.

Rare (1 to 10 animals in 10,000 treated): anorexia, behavioural disorder.

Very rare (less than 1 animal in 10,000 treated, including isolated reports): bradycardia, hypotension, dyspnoea, loss of consciousness, sedation, recumbency, muscle weakness, hiding.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system.

Overdose: After up to 5 times the recommended dose for 6 months in young healthy cats, non-progressive increases in triglyceride levels were noted in male cats, an increase in liver to brain weight ratio was observed and liver vacuolation was noted in two animals. One male cat in the 5x group was diagnosed with diabetic ketoacidosis and had elevated serum liver parameters on day 50 of dosing. Other adverse reactions observed were consistent with those listed above.

Storage and disposal

• Do not store above 30°C.
• Shelf life after first opening the bottle: 3 months.
• Medicines should not be disposed of via wastewater. Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable.

Active ingredient: Capromorelin tartrate 20 mg per ml (equivalent to 15.4 mg capromorelin).

Other ingredients: Sodium methyl parahydroxybenzoate (E 219) 1.5 mg per ml, Sodium propyl parahydroxybenzoate (E 217) 0.25 mg per ml, Sodium chloride, Citric acid, Sucralose, Vanillin, Povidone (K-90), Glycerol, Maltitol liquid, Magnasweet 110 (glycyrrhizic acid, monoammonium glycyrrhizinate), Purified water.

External content warning: this link will take you to a third party website.
We cannot guarantee the Patient Information Leaflet is accurate and is for reference only.